ReviewAntibiotics (Basel, Switzerland)2022
Use of Antimicrobials for Bloodstream Infections in the Intensive Care Unit, a Clinically Oriented Review.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Pathogenic spectrum, antibiotic resistance, and risk factors for 28-day mortality in pediatric bloodstream infection-associated sepsis: a 10-year retrospective cohort study.Microbiology spectrum · 2026Article
- Potential drug-drug interactions and 30-day mortality in ICU patients with bloodstream infection: a single-center retrospective study.BMC infectious diseases · 2026Article
- Article
- Real-life evaluation of BioFire® BCID2 and Vitek® REVEALTM for Gram-negative bloodstream infections in critical care.PloS one · 2026Article
- An Algorithm for Rapid and Low-Cost Detection of Carbapenemases Directly from Positive Blood Cultures Using an Immunochromatographic Test.Antibiotics (Basel, Switzerland) · 2025Article
- The Impact of the COVID-19 Pandemic on Antimicrobial Resistance Trends in a Tertiary Care Teaching Hospital: A Ten-Year Surveillance Study.Antibiotics (Basel, Switzerland) · 2025Article
- Risk factors associated with mortality and pathogen characteristics of bloodstream infection-induced severe sepsis in the pediatric intensive care unit: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2025Article
- Strategies to reduce 28-day mortality in adult patients with bacteremia in the emergency department.BMC infectious diseases · 2024Article
- Bloodstream Infection in the Intensive Care Unit: Evolving Epidemiology and Microbiology.Antibiotics (Basel, Switzerland) · 2024Review
- Impact of Multiplex PCR in the Therapeutic Management of Severe Bacterial Pneumonia.Antibiotics (Basel, Switzerland) · 2024Review
- Rapid identification of pathogens in blood serum via Raman tweezers in combination with advanced processing methods.Biomedical optics express · 2023Article
- Clinical Use of Intravenous Fosfomycin in Critical Care Patients in Taiwan.Pathogens (Basel, Switzerland) · 2023Article
- Evaluation of XGEN Multi Sepsis Flow Chip Molecular Assay for Early Diagnosis of Bloodstream Infection.Current microbiology · 2023Article
- Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study.Intensive care medicine · 2023Article
- Editorial for Special Issue "Antimicrobial Therapy in Intensive Care Unit".Antibiotics (Basel, Switzerland) · 2023Article
- When and How to Use MIC in Clinical Practice?Antibiotics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bloodstream infections (BSIs) in critically ill patients are associated with significant mortality. For patients with septic shock, antibiotics should be administered within the hour. Probabilistic treatment should be targeted to the most likely pathogens, considering the source and risk factors for bacterial resistance including local epidemiology. Source control is a critical component of the management. Sending blood cultures (BCs) and other specimens before antibiotic administration, without delaying them, is key to microbiological diagnosis and subsequent opportunities for antimicrobial stewardship. Molecular rapid diagnostic testing may provide faster identification of pathogens and specific resistance patterns from the initial positive BC. Results allow for antibiotic optimisation, targeting the causative pathogen with escalation or de-escalation as required. Through this clinically oriented narrative review, we provide expert commentary for empirical and targeted antibiotic choice, including a review of the evidence and recommendations for the treatments of extended-spectrum β-lactamase-producing, AmpC-hyperproducing and carbapenem-resistant Enterobacterales; carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.